Investigating potential protein markers of cardiovascular disease in children with type 1 diabetes mellitus.
biomarkers
cardiovascular disease
paediatrics
type 1 diabetes mellitus
Journal
Proteomics. Clinical applications
ISSN: 1862-8354
Titre abrégé: Proteomics Clin Appl
Pays: Germany
ID NLM: 101298608
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
01
11
2020
received:
22
07
2020
accepted:
17
12
2020
pubmed:
16
2
2021
medline:
21
1
2022
entrez:
15
2
2021
Statut:
ppublish
Résumé
Type 1 diabetes mellitus (T1DM) is a metabolic disease characterized by dysglycaemia. Cardiovascular disease (CVD) is a major complication among T1DM patients and the leading cause of mortality later in life. The study subjects consisted of T1DM children with poor glycemic control (HbA1c > 7.5%) and healthy age and gender matched controls. Venous blood samples were collected and tested by utilizing a novel immunoassay panel with 96 protein biomarkers. Data were analyzed using non-linear regression analysis and the expression of biomarkers was compared between T1DM and healthy control groups using an unpaired student's t-test. Dynamic principal component analysis (PCA) was operated based on the differentially expressed proteins. Ten T1DM children and 10 healthy controls were analyzed. Twelve CVD markers show significant differential expression between T1DM patients and healthy controls (p < 0.05). Dynamic PCA clustering based on differentially expressed proteins demonstrated an obvious clustering between the two populations. This preliminary study reveals the feasibility of utilizing a novel immunoassay panel to investigate potential biomarkers for predicting incipient CVD in children with T1DM. In future, longitudinal studies are required to track the relationships between measurements of the selected protein markers and the development of CVD in T1DM patients.
Sections du résumé
BACKGROUND
Type 1 diabetes mellitus (T1DM) is a metabolic disease characterized by dysglycaemia. Cardiovascular disease (CVD) is a major complication among T1DM patients and the leading cause of mortality later in life.
METHODS
The study subjects consisted of T1DM children with poor glycemic control (HbA1c > 7.5%) and healthy age and gender matched controls. Venous blood samples were collected and tested by utilizing a novel immunoassay panel with 96 protein biomarkers. Data were analyzed using non-linear regression analysis and the expression of biomarkers was compared between T1DM and healthy control groups using an unpaired student's t-test. Dynamic principal component analysis (PCA) was operated based on the differentially expressed proteins.
RESULTS
Ten T1DM children and 10 healthy controls were analyzed. Twelve CVD markers show significant differential expression between T1DM patients and healthy controls (p < 0.05). Dynamic PCA clustering based on differentially expressed proteins demonstrated an obvious clustering between the two populations.
CONCLUSIONS
This preliminary study reveals the feasibility of utilizing a novel immunoassay panel to investigate potential biomarkers for predicting incipient CVD in children with T1DM. In future, longitudinal studies are required to track the relationships between measurements of the selected protein markers and the development of CVD in T1DM patients.
Identifiants
pubmed: 33587825
doi: 10.1002/prca.202000060
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2000060Informations de copyright
© 2021 Wiley-VCH GmbH.
Références
A. D. Association. (2019). Classification and diagnosis of diabetes: Standards of medical care in diabetes-2019. Diabetes Care, 42, S13.
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., Da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018). IDF diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Research and Clinical Practice, 138, 271-281.
Holt, R. I., Cockram, C., Flyvbjerg, A., & Goldstein, B. J. (2017) Textbook of diabetes, John Wiley & Sons.
Secrest, A. M., Becker, D. J., Kelsey, S. F., Laporte, R. E., & Orchard, T. J. (2010). Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes, 59, 3216.
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., & Sherwin, R. S. (2009). Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care, 32, 187.
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014). Glycemic control and excess mortality in type 1 diabetes. The New England Journal of Medicine, 371, (1972).
Control, D., o. D. Interventions, C. T. E., & Group, C. S. R. (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine, 353, 2643.
Pogach, L., Conlin, P. R., Hobbs, C., & Vigersky, R. A., Federal Practitioner, (2011).
Purnell, J. Q., Hokanson, J. E., Marcovina, S. M., Steffes, M. W., Cleary, P. A., Brunzell, J. D. (1998). Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. Diabetes control and complications trial. The Journal of the American Medical Association, 280, 140.
Rasmussen, L. M., Tarnow, L., Hansen, T. K., Parving, H.-H., Flyvbjerg, A. (2006). Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. European Journal of Endocrinology., 154, 75.
Hoq, M., Karlaftis, V., Mathews, S., Burgess, J., Donath, S. M., Carlin, J., Monagle, P., Ignjatovic, V. (2019). A prospective, cross-sectional study to establish age-specific reference intervals for neonates and children in the setting of clinical biochemistry, immunology and haematology: the HAPPI Kids study protocol. BMJ Open, 9, e025897.
Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Bucht Thorsen, S., Ekman, D., Eriksson, A., Rennel Dickens, E., Ohlsson, S., Edfeldt, G., Andersson, A.-C., Lindstedt, P., Stenvang, J., Gullberg, M., Fredriksson, S. (2014). Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One, 9, e95192.
Berezin, A. E. (2016). BMJ Publishing Group Ltd and British Cardiovascular Society.
Watkins, R. A., Evans-Molina, C., Blum, J. S., Dimeglio, L. A. (2014). Established and emerging biomarkers for the prediction of type 1 diabetes: A systematic review. Translational Research, 164, 110.
The Emerging Risk Factors Collaboration. (2010). Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 375, 2215.
Brand, R. E., Nolen, B. M., Zeh, H. J., Allen, P. J., Eloubeidi, M. A., Goldberg, M., Elton, E., Arnoletti, J. P., Christein, J. D., Vickers, S. M., Langmead, C. J., Landsittel, D. P., Whitcomb, D. C., Grizzle, W. E., Lokshin, A. E. (2011). Serum biomarker panels for the detection of pancreatic cancer. Clinical Cancer Research, 17, 805.
Targher, G., Chonchol, M., Zoppini, G., Franchini, M. (2011). Hemostatic disorders in type 1 diabetes mellitus. Seminars in Thrombosis and Hemostasis, 37, 058.
Darmanis, S., Nong, R. Y., Vänelid, J., Siegbahn, A., Ericsson, O., Fredriksson, S., Bäcklin, C., Gut, M., Heath, S., Gut, I. G., Wallentin, L., Gustafsson, M. G., Kamali-Moghaddam, M., Landegren, U. (2011). ProteinSeq: High-performance proteomic analyses by proximity ligation and next generation sequencing. PLoS One, 6, e25583.
Kaye, D. M., Vaddadi, G., Gruskin, S. L., Du, X.-J., Esler, M. D. (2000). Reduced myocardial nerve growth factor expression in human and experimental heart failure. Circulation Research, 86, e80.
Eklund, L., Kangas, J., Saharinen, P. (2017). Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems. Clinical Science, 131, 87.
Lu, X., Hu, M. C. (2017). Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease. Kidney Diseases, 3, 15.
Bayomy, N. A., Fawzy, M. S., Badawy, A., & AlSel, B. T. A., International Journal of Clinical and Experimental Medicine, (2019), 12, 1600.
Lorbeer, R., Baumeister, S. E., Dörr, M., Felix, S. B., Nauck, M., Grotevendt, A., Markus, M. R. P., Von Sarnowski, B., Völzke, H., Vasan, R. S., Wallaschofski, H., Lieb, W. (2015). Angiopoietin-2, its soluble receptor Tie-2 and subclinical cardiovascular disease in a population-based sample. Heart, 101, 178.
Pérez De Ciriza, C., Lawrie, A., & Varo, N. (2015). Osteoprotegerin in cardiometabolic disorders. International Journal of Endocrinology, 2015, 1.
Shiasi, K., Talebian, F., Khamechi, S. P., Nikoueinejad, H., & Sehat, M., Azarbad, Z., & Einollahi, B., Nephro-Urology Monthly, (2017), 9.
Naka, K. K., Papathanassiou, K., Bechlioulis, A., Pappas, K., Tigas, S., Makriyiannis, D., Antoniou, S., Kazakos, N., Margeli, A., Papassotiriou, I., Tsatsoulis, A., Michalis, L. K. (2018). Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2 diabetes mellitus. Clinical Biochemistry, 53, 31.
Fujikawa, T., Chuang, J.-C., Sakata, I., Ramadori, G., & Coppari, R. (2010). Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proceedings of the National Academy of Sciences of the United States of America, 107, 17391.
Zhang, D., Gava, A. L., Van Krieken, R., Mehta, N., Li, R., Gao, B.o, Desjardins, E. M., Steinberg, G. R., Hawke, T., Krepinsky, J. C. (2019). The caveolin-1 regulated protein follistatin protects against diabetic kidney disease. Kidney International, 96, 1134.
Ueland, T., Aukrust, P., Aakhus, S., Smith, C., Endresen, K., Birkeland, K. I., Gullestad, L., Johansen, O. E. (2012). Activin A and cardiovascular disease in type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 9, 234.
Lee, S. I., Patel, M., Jones, C. M., Narendran, P. (2015). Cardiovascular disease and type 1 diabetes: Prevalence, prediction and management in an ageing population. Therapeutic Advances in Chronic Disease, 6, 347.
Feldreich, T., Nowak, C., Fall, T., Carlsson, A. C., Carrero, J.-J., Ripsweden, J., Qureshi, A. R., Heimbürger, O., Barany, P., Stenvinkel, P., Vuilleumier, N., Kalra, P. A., Green, D., Ärnlöv, J. (2019). Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. Journal of Nephrology, 32, 111.
Moreno-Ajona, D., Irimia, P., Rodríguez, J. A., García-Velloso, M. J., López-Fidalgo, J., Fernández-Alonso, L., Grochowitz, L., Muñoz, R., Domínguez, P., Gállego-Culleré, J., & Martínez-Vila, E. (2020). Correction to: Cardiac rupture complicating acute myocardial infarction: The clinical features from an observational study and animal experiment. BMC Cardiovascular Disorders., 20.
Salem, M., El Behery, S., Adly, A., Khalil, D., & El Hadidi, E. (2009), Early predictors of myocardial disease in children and adolescents with type 1 diabetes mellitus. Pediatric Diabetes, 10, 513.
Eshaq, R. S., & Harris, N. R. (2019). Loss of Platelet Endothelial cell adhesion molecule-1 (PECAM-1) in the diabetic retina: Role of matrix metalloproteinases. Investigative Opthalmology & Visual Science, 60, 748.
Therkelsen, K. E., Abraham, T. M., Pedley, A., Massaro, J. M., Sutherland, P., Hoffmann, U., Fox, C. S. (2016). Association between prolactin and incidence of cardiovascular risk factors in the Framingham heart study. Journal of the American Heart Association, 5, e002640.
Metz, T. O., Qian, W.-J., Jacobs, J. M., Gritsenko, M. A., Moore, R. J., Polpitiya, A. D., Monroe, M. E., Camp Ii, D. G., Mueller, P. W., & Smith, R. D. (2008). Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset. Journal of Proteome Research, 7, 698.
Bjelosevic, S., Pascovici, D., Ping, H., Karlaftis, V., Zaw, T., Song, X., Molloy, M. P., Monagle, P., & Ignjatovic, V. (2017). quantitative age-specific variability of plasma proteins in healthy neonates, children and adults. Molecular & Cellular Proteomics, 16, 924.
Parkin, G. M., Clarke, C., Takagi, M., Hearps, S., Babl, F. E., Davis, G. A., Anderson, V., Ignjatovic, V. (2019). Plasma tumor necrosis factor alpha is a predictor of persisting symptoms post-concussion in children. Journal of Neurotrauma, 36, 1768.